Limiting glucocorticoid secretion increases the anorexigenic property of Exendin-4

OBJECTIVE: Glucagon-like peptide-1 (GLP-1) analogs are attractive options for the treatment of type II diabetes and obesity because of their incretin and anorexigenic effects. Peripheral administration of the GLP-1R agonist Exendin-4 (Ex-4) also increases glucocorticoid secretion in rodents and huma...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Shin J., Diener, Katharina, Kaufman, Sharon, Krieger, Jean-Philippe, Pettersen, Klaus G., Jejelava, Nino, Arnold, Myrtha, Watts, Alan G., Langhans, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4921942/
https://www.ncbi.nlm.nih.gov/pubmed/27408779
http://dx.doi.org/10.1016/j.molmet.2016.04.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4921942/
https://www.ncbi.nlm.nih.gov/pubmed/27408779
http://dx.doi.org/10.1016/j.molmet.2016.04.008

Ejemplares similares